1. Limitations and advances in new treatments and future perspectives of corneal blindness
- Author
-
Denny Marcos Garcia, Rosalia Antunes-Foschini, Leidiane Adriano, Eduardo Rocha, Luis Fernando Nominato, Marina Zilio Fantucci, Amanda Pires Barbosa, Adriana de Andrade Batista Murashima, Lara Cristina Dias, and Monica Alves
- Subjects
medicine.medical_specialty ,genetic structures ,Genetic therapy ,Corneal diseases ,Cell- and tissue-based therapy ,medicine.medical_treatment ,Anti-Inflammatory Agents ,Stem cells ,Blindness ,Anabolic Agents ,Cornea ,03 medical and health sciences ,Corneal blindness ,0302 clinical medicine ,Corneal surgery ,Humans ,Medicine ,Intensive care medicine ,Corneal transplantation ,Wound Healing ,business.industry ,Corneal Diseases ,General Medicine ,RE1-994 ,eye diseases ,Corneal transparency ,Ophthalmology ,030221 ophthalmology & optometry ,Corneal wound ,sense organs ,business ,Corneal Injuries - Abstract
This review is intended to describe the therapeutic approaches for corneal blindness, detailing the steps and elements involved in corneal wound healing. It also presents the limitations of the actual surgical and pharmacological strategies used to restore and maintain corneal transparency in terms of long-term survival and geographic coverage. In addition, we critically review the perspectives of anabolic agents, including vitamin A, hormones, growth factors, and novel promitotic and anti-inflammatory modulators, to assist corneal wound healing. We discuss the studies involving nanotechnology, gene therapy, and tissue reengineering as potential future strategies to work solely or in combination with corneal surgery to prevent or revert corneal blindness.
- Published
- 2021